Eli Lilly's Weight-Loss Drug Zepbound Now Available in U.S. Pharmacies

The FDA-approved medication, intended for adults with obesity or weight-related medical issues, has shown significant weight loss results in clinical trials.

Zepbound, a new weight-loss medication by Eli Lilly, is now available in U.S. pharmacies. The drug, which contains the active ingredient tirzepatide, was approved by the FDA last month for chronic weight management.
Zepbound is intended for adults with obesity or those who are overweight with at least one weight-related medical issue. It works by mimicking two hormones, GLP-1 and GIP, which stimulate the release of insulin in the body, reducing appetite and slowing the rate at which food empties from the stomach.
In clinical trials, Zepbound was found to yield more than 20% average weight loss at higher doses over 72 weeks, more than seen with other approved weight loss medications.
Zepbound's main side effects include gastrointestinal issues like nausea, vomiting, constipation and diarrhea. The drug's label also warns about potential inflammation of the pancreas, gallbladder problems, low blood sugar, acute kidney injury, damage to the retina in people with type 2 diabetes, and suicidal behavior or thinking.
Before insurance, Zepbound will cost about $1,060 per month. Eli Lilly is offering a savings card for people with private insurance to get Zepbound for $25 for a one- or three-month prescription if their plans cover it. For those whose plans don't cover Zepbound, the savings card would lower the cost to $550 per month.

One America News Network